Why RCI Became the First in the State to Adopt ProFound AI as its Breast AI Solution for Mammography

September 20, 2022
Category: iNFORMED - Blog

Iowa’s largest radiology group, Radiology Consultants of Iowa (RCI), offers a wide range of imaging services for patients, including breast cancer screening. In addition to the mammograms done at their imaging center, which is accredited by the American College of Radiology (ACR) as a Breast Imaging Center of Excellence, RCI radiologists also read mammography for more than 10 other hospitals, including a high‐risk clinic and a local OBGYN group, totaling an average of about 7,000 exams per year.


“At RCI, we pride ourselves on al... Continue reading

Tags: Customer Story 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Tomosynthesis Software Technology
rci-building.jpg

iCAD To Participate in The Lake Street Capital Markets 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022

September 07, 2022
Category: Press Releases

NASHUA, N.H., September 7, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the Lake Street Capital Markets, 6th Annual Best Ideas Growth (BIG6) Conference, taking place Wednesday, September 14, 2022 in New York City.

Stacey Stevens, President and CEO of iCAD, Inc. is scheduled to meet with investors on Wednesday, September 14, 2022. If you are interested in scheduling a me... Continue reading

Tags: Press Releases

iCAD Customers in the U.S. and Europe Increasingly Adopting Company’s Full Suite of Breast AI Technologies via Subscription Model

August 29, 2022
Category: Press Releases

Flexible subscription model accelerates deployment of iCAD’s Breast AI Suite, the only complete solution designed to comprehensively address today’s top imaging challenges

 

NASHUA, N.H. – August 29, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that a growing number of hospitals and imaging centers in the U.S. and Europe are increasingly choosing to adopt iCAD... Continue reading

Tags: Press Releases

iCAD Reports Financial Results For Second Quarter 2022

August 10, 2022
Category: Press Releases

Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities

 

Cancer Detection revenue grew 10.4% compared to the second quarter of 2021

 

Company to host conference call and webcast today at 4:30 PM ET

 

NASHUA, N.H. – August 10, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing inno... Continue reading

Tags: Press Releases

iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

July 27, 2022
Category: Press Releases

NASHUA, N.H. – July, 27 2022 –  iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022.

 

August 10, 2022 at 4:30 PM ET

Domestic: 888-506-0062              &nb... Continue reading

Tags: Press Releases

iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology

July 13, 2022
Category: Press Releases

Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general population


NASHUA, N.H. – July 13, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the Company will showcase and demonstrate the complete portfolio of its Breast AI solutions, including ProFound AI®, PowerLo... Continue reading

Tags: Press Releases

ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series

June 29, 2022
Category: Press Releases

Leading radiologists to highlight clinical examples demonstrating power of iCAD’s complete suite of ProFound AI Breast Health Solutions

 

NASHUA, N.H. – June 29, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that leading radiologists will highlight clinical examples demonstrating the power of ProFound AI® Ris... Continue reading

Tags: Press Releases

iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk

June 07, 2022
Category: Press Releases

Leading experts, including distinguished researchers from the Karolinska Institutet and clinicians using it in daily practice, to discuss significant impact and value of technology

 

NASHUA, N.H. – June 7, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its next webinar, titled “Risk Assessm... Continue reading

Tags: Press Releases

iCAD Announces CFO Transition

May 25, 2022
Category: Press Releases

Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately


NASHUA, N.H., May 25, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno as interim Chief Financial Officer (CFO), effective immediately. Mr. Sarno will assist with the transition as Charles Carter departs the Company this month.


Continue reading
Tags: Press Releases

New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography

May 18, 2022
Category: Press Releases

Research presented at the 2022 SBI/ACR Breast Imaging Symposium confirms ProFound AI significantly enhances radiologists’ screening performance


NASHUA, N.H., May 18, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting ProFound AI® for Digital Breast Tomosynthesis (DBT) will be presented at the Society of Breast Imaging (SBI/ACR) Breast Imaging Symposium, taking place May 16-19 in Sava... Continue reading

Tags: Press Releases

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models

May 17, 2022
Category: iNFORMED - Blog

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

   

iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital Breast Tomosynthesis (DBT) – the world’s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation based on age, breast density and mammographic fea... Continue reading

Tags: 3D Mammography Artificial Intelligence Breast Cancer Detection Breast Density Breast Tomosynthesis Density Assessment Software Technology
2022-05-17-ProFound-AI-Risk-Blog.jpg

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models

May 16, 2022
Category: Press Releases

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population

  

NASHUA, N.H., May 16, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that promising clinical research supporting ProFou... Continue reading

Tags: Press Releases

iCAD to Present at the Spring Into Action – Best Ideas Virtual Investor Conference on May 17th, 2022

May 12, 2022
Category: Press Releases

NASHUA, N.H., May 12, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action – Best Ideas Virtual Investor Conference, which is being held virtually on May 16th – 20th, 2022.


Stacey Stevens, President and CEO of iCAD, Inc. will pre... Continue reading

Tags: Press Releases

iCAD Reports Financial Results for First Quarter Ended March 31, 2022

May 11, 2022
Category: Press Releases

Company to host conference call and webcast today at 4:30 PM ET

 

NASHUA, N.H. – May 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022.

 

Highlights:

Commercial reorganization shows early success leading to a ProFound AI® enterprise agreement at a world-renowned academic research... Continue reading
Tags: Press Releases

iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Clinical and IT Experts from Wake Radiology

April 28, 2022
Category: Press Releases

Leading healthcare provider with 14 imaging centers in North Carolina identified ProFound AI as the premier solution in a competitive trial based on unique workflow benefits and multivendor flexibility

 

 NASHUA, N.H. – April 28, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that the next event in its “ProFound Insights, ProFound Impact” webinar series w... Continue reading

Tags: Press Releases

iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11

April 27, 2022
Category: Press Releases

NASHUA, N.H. – April 27, 2022 –  iCAD®, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11.

 

Wednesday, May 11th at 4:30 PM ET

Domestic:                    888-506-0062

Continue reading

Tags: Press Releases

iCAD Announces Significant Commercial Momentum for ProFound AI® Among Customers Equipped with the Leading Provider of 3D Mammography Systems

April 26, 2022
Category: Press Releases

Customers report continued workflow advantages and clinical superiority with iCAD’s suite of AI‐powered breast health solutions, compared to other available breast AI solutions

 

 

NASHUA, N.H. – April 26, 2022 ‐ iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced significant commercial momentum for ProFound AI®, driving attachment to the leading provider of 3D... Continue reading

Tags: Press Releases

iCAD Announces Estimated Q1 Revenue and Upcoming Board and CFO Transitions

April 21, 2022
Category: Press Releases

Company expects preliminary estimated revenue to be .5 million

 

Timothy Norris Irish Appointed Chairman of the Board of Directors, Successor CFO search underway

 

NASHUA, N.H. – April 21, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader pro... Continue reading

Tags: Press Releases

iCAD Launches ProFound Insights, ProFound Impact Webinar Series on April 27

April 19, 2022
Category: Press Releases

First event to feature Kettering Health, a leading enterprise breast care provider with 14 breast centers across southwest Ohio

 

NASHUA, N.H. – April 19, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will launch a new webinar series, ProFound Insights, ProFound Impact, which will highl... Continue reading

Tags: Press Releases

iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment

April 05, 2022
Category: Press Releases

Multiple leading institutions leverage the versatility of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancers

 

 

NASHUA, N.H. – April 5, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that additional patients have been treated under the international multi-center GLIOX trial and customers globally are continui... Continue reading

Tags: Press Releases

© iCAD Inc.  All rights reserved.  iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

Facebook icon Twitter icon LinkedIn icon